Head to Head Survey: Corium International (CORI) vs. Opko Health (OPK)

Corium International (NASDAQ: CORI) and Opko Health (NASDAQ:OPK) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Insider & Institutional Ownership

89.1% of Corium International shares are owned by institutional investors. Comparatively, 22.9% of Opko Health shares are owned by institutional investors. 45.7% of Corium International shares are owned by insiders. Comparatively, 40.2% of Opko Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Corium International has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Earnings and Valuation

This table compares Corium International and Opko Health’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corium International $31.86 million 11.77 -$47.79 million ($1.67) -6.22
Opko Health $1.22 billion 2.30 -$25.08 million ($0.19) -26.47

Opko Health has higher revenue and earnings than Corium International. Opko Health is trading at a lower price-to-earnings ratio than Corium International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Corium International and Opko Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 6 0 3.00
Opko Health 0 2 5 0 2.71

Corium International currently has a consensus target price of $13.00, indicating a potential upside of 25.24%. Opko Health has a consensus target price of $14.21, indicating a potential upside of 182.59%. Given Opko Health’s higher possible upside, analysts plainly believe Opko Health is more favorable than Corium International.

Profitability

This table compares Corium International and Opko Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -482.64% -62.37%
Opko Health -9.45% -5.17% -3.94%

Summary

Opko Health beats Corium International on 8 of the 14 factors compared between the two stocks.

About Corium International

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

About Opko Health

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit